K. Bauer
Cardiology and Cardiovascular Medicine · New England Journal of Medicine · 2001–2020
A researcher in the Science corpus: 10 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Cardiology and Cardiovascular Medicine — 25 citations into it
- Internal Medicine — 22 citations into it
Whom K. Bauer trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from K. Bauer's perspective
Ordered by how strongly the researchers K. Bauer trusts endorse each paper. Same corpus, a different order for every researcher.
- GRADE guidelines: 2. Framing the question and deciding on important outcomes. (Journal of Clinical Epidemiology)
- GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. (Journal of Clinical Epidemiology)
- GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. (Journal of Clinical Epidemiology)
- GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. (Journal of Clinical Epidemiology)
- Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. (American Journal of Medicine)
- Ensuring trust in COVID-19 data (Medicine)
- Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. (JAMA cardiology)
- Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. (Archives of Internal Medicine)
- Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. (The Lancet)
- Quantifying heterogeneity in a meta‐analysis (Statistics in Medicine)
Their papers
- Extrapulmonary manifestations of COVID-19 (2020) — 2,748 citations
- Rivaroxaban for Thromboprophylaxis in High‐Risk Ambulatory Patients with Cancer (2019) — 609 citations
- American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. (2018) — 665 citations
- Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. (2009) — 993 citations
- Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) — 751 citations
- Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. (2005) — 1,312 citations
- Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. (2003) — 777 citations
- Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. (2002) — 754 citations
- Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. (2001) — 650 citations
- Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. (2001) — 634 citations